Transforming targeted cancer therapy with PROTACs: A forward-looking perspective
Year: 2021
Type: review
Abstract: Small-molecule targeted protein degraders have in recent years made a great impact on the strategies of many industry and academic cancer research endeavours. We seek here to provide a concise perspective on the opportunities and challenges that lie ahead for bifunctional degrader molecules, so-called 'Proteolysis Targeting Chimeras (PROTACs),' in the context of cancer therapy. We highlight high-profile studies that support the potential for PROTAC approaches to broaden drug target scope, address drug resistance, enhance target selectivity and provide tissue specificity, but also assess where the modality is yet to fully deliver in these contexts. Future opportunities presented by the unique bifunctional nature of these molecules are also discussed.
Source: Current Opinion in Pharmacology
Institutions: University of Dundee, Boehringer Ingelheim (Austria)
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $3,210
Funders: Boehringer Ingelheim, Eisai
OpenAlex ID: W3143618917
